Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

alm_v2

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

March 17, 2016 Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …
News
bayercross3

FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016 Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
News
amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016 Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
News
7-0_careers_taleobanner_900x600

Baxter to cut stake in Baxalta

March 17, 2016 Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter

Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …
News
asthma_inhalers

Vectura agree £441m merger with Skyepharma

March 16, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Skyepharma, UK, biotech, merger, vectura

Vectura (LON: VEC) and Skyepharma (LON: SKP), two UK-based pharma companies, have joined together in a deal worth £441m. The …
News

Orexigen takes back rights to its weigh management drug from Takeda

March 16, 2016 Business Services, Manufacturing and Production, Sales and Marketing Contrave, Orexigen Therapeutics, akeda Pharmaceuticals

Orexigen Therapeutics (Nasdaq: OREX) has taken back the rights to its weight management drug from Japanese pharma giant Takeda Pharmaceuticals …
News
shutterstock_159488225

Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine

March 16, 2016 Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech

Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …
News

Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy

March 16, 2016 Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development

Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …
News
celatorpharmalogo

Celator’s shares jump on positive late-stage trials for leukaemia drug

March 16, 2016 Business Services, Research and Development, Sales and Marketing Celator Pharmaceuticals, EMA, US FDA, Vyxeos, drug trials, phase III

Shares in trial-stage Celator Pharmaceuticals (Nasdaq: CPXX) soared gaining over four times in value as the company announced late-stage trials …
News
abbottweb

FDA says benefits outweigh risks in Abbott’s heart stent, Absorb

March 16, 2016 Research and Development, Sales and Marketing Abbott, absorb, bioresorbable, coronary artery disease

An independent panel convened by the US Food and Drug Administration (FDA) has unanimously voted that the benefits of Absorb, …
News
teva_copy

Teva says closing buy of Allergan’s generics biz may take longer

March 16, 2016 Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva

Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …
News
invivo

UPDATE: InVivo Therapeutics prices public offering at $7.50 per share to raise $28 million

March 15, 2016 Business Services, Manufacturing and Production, Sales and Marketing InVivo, Share price, Stake sale

InVivo Therapeutics (Nasdaq: NVIV) on Tuesday said it plans to raise about $28 million via a public offering of over …
News
valeant_logo

Valeant cuts 2016 sales, earnings outlook; shares plunge over 47%

March 15, 2016 Business Services, Manufacturing and Production, Sales and Marketing Valeant Pharma, fourth quarter, full year, results

Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …
News

Cellnovo, Roche sign deal to integrate diabetes platforms

March 15, 2016 Manufacturing and Production, Sales and Marketing Cellnovo, Roche, diabetes

Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to …
News
shutterstock_244903099

InVivo Therapeutics to sell stake in company; shares drop

March 15, 2016 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing InVivo Therapeutics, Stake sale, stocks

InVivo Therapeutics (Nasdaq: NVIV) said it plans to sell an additional stake in the company to raise funds for its ongoing …
News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026